drugset / Trial / NCT04779242
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
Timeline
- Start
- 2021-02-25
- Primary completion
- 2024-03-27
- Completion
- 2024-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | Intravenous |
| Subject | Omadacycline | Small molecule | 300 mg | Intravenous |